{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacology%2C+Clinical", "query": { "condition": "Pharmacology, Clinical" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 111, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacology%2C+Clinical&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T10:56:51.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01519557", "title": "Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "DAR-100A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 68, "start_date": "2011-04", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2015-03-04", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519557" }, { "nct_id": "NCT03302494", "title": "WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke" ], "interventions": [ { "name": "Coherex WaveCrest® Left Atrial Appendage Occlusion System", "type": "DEVICE" }, { "name": "Watchman® LAA Closure Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Coherex Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2017-12-27", "completion_date": "2023-12-21", "has_results": true, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03302494" }, { "nct_id": "NCT00012129", "title": "Chemotherapy in Treating Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "liposomal annamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1998-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012129" }, { "nct_id": "NCT03842800", "title": "Characterizing Clinical and Pharmacological Neuroimaging Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cognitive Impairment" ], "interventions": [ { "name": "MRI", "type": "OTHER" }, { "name": "Ketamine", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 143, "start_date": "2013-04-01", "completion_date": "2018-08-31", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03842800" }, { "nct_id": "NCT01112670", "title": "The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "21 Years to 60 Years" }, "enrollment_count": 33, "start_date": "2009-11", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01112670" }, { "nct_id": "NCT05999383", "title": "Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "THC", "Cannabis", "Cannabis Use", "Cannabis Smoking", "Tobacco Use", "Vaping" ], "interventions": [ { "name": "Cannabis", "type": "DRUG" }, { "name": "Nicotine", "type": "DRUG" }, { "name": "Pax Loose Leaf Vaporizer", "type": "DEVICE" }, { "name": "Placebo Marijuana", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2025-07-01", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05999383" }, { "nct_id": "NCT02522481", "title": "Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Lumason", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bracco Diagnostics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-09-24", "completion_date": "2018-02-25", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 10, "location_summary": "Tucson, Arizona • La Jolla, California • West Hills, California + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02522481" }, { "nct_id": "NCT06092346", "title": "A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "AMPD3, OMIM*102772, AMP Deaminase Deficiency", "AK1, OMIM *103000, Adenylate Kinase Deficiency", "AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency", "TPMT, OMIM *187680, Thoipurines, Poor Metabolism of", "IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11", "APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency", "HPRT1, OMIM *308000 Lesch-Nyhan Disease", "XDH, OMIM *607633, Xanthinuria Type 1", "SLC2A9, OMIM *606142 Hypouricemia", "SLC22A12, OMIM *607096 Hypouricemia", "PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease", "PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity", "AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia", "ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35", "ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency", "PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency", "ADA2, OMIM *607575,Sneddon Syndrome; VAIHS", "CAD, *1140120, Developmental and Epileptic Encephalopathy", "UPB1, OMIM *606673, Beta-ureidopropionase Deficiency", "DPYS, OMIM *613326, Dihydropyrimidinase Deficiency", "DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency", "DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)", "UMPS, OMIM *613891, Orotic Aciduria", "NT5C3A, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency", "UNG, OMIM *191525, Hyper-IgM Syndrome 5", "AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2", "Purine-Pyrimidine Metabolism", "Metabolic Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "100 Years", "sex": "ALL", "summary": "1 Month to 100 Years" }, "enrollment_count": 999, "start_date": "2023-12-19", "completion_date": "2099-01-01", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06092346" }, { "nct_id": "NCT04817228", "title": "A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Venous Leg Ulcer", "Diabetic Foot Ulcer" ], "interventions": [ { "name": "EscharEx (EX-02 formulation)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediWound Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 12, "start_date": "2021-04-21", "completion_date": "2022-05-20", "has_results": false, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 3, "location_summary": "Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina", "locations": [ { "city": "Tamarac", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04817228" }, { "nct_id": "NCT03282513", "title": "A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "AG-120 (Ivosidenib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agios Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 33, "start_date": "2017-09-26", "completion_date": "2018-03-31", "has_results": false, "last_update_posted_date": "2018-04-27", "last_synced_at": "2026-06-26T10:56:51.468Z", "location_count": 2, "location_summary": "Lakewood, Colorado • Minneapolis, Minnesota", "locations": [ { "city": "Lakewood", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03282513" } ] }